Intra-Cellular Therapies (ITCI)

P/S ratio as of March 2025 (TTM): 20.5

According to Intra-Cellular Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.2. At the end of 2024 the company had a P/S ratio of 13.2.

P/S ratio history for Intra-Cellular Therapies from 2014 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	13.2	-11.36%
2023	14.9	-25.87%
2022	20.1	-61.45%
2021	52.2	-54.05%
2020	114	-99.64%
2019	> 1000
2018	N/A
2017	N/A
2016	N/A	-100%
2015	> 1000	7862.53%
2014	951

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
MediciNova MNOV	N/A	N/A	🇺🇸 USA
Curis CRIS	2.34	-88.59%	🇺🇸 USA
Xencor XNCR	6.96	-66.10%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Intra-Cellular Therapies (ITCI)

P/S ratio as of March 2025 (TTM): 20.5